BRAF and lung carcinoma: These findings demonstrate exarafenib and binimetinib combination as a promising therapeutic strategy for BRAF-mutant lung cancer, offering superior efficacy and the potential to decrease exarafenib doses to maintain or enhance therapeutic index while eliciting efficacy.